Drugs / Biocon Insulin N
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04022304 | Jun → Dec 2019 | — | Biocon Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Biocon Insulin N | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04022304 ↗ |
| Modality | Protein / enzyme biologic | “Biocon Insulin N is an intermediate-acting isophane suspension of human insulin produced by recombinant deoxyribonucleic acid(rDNA) technology” NCT04022304 ↗ |
| Route | Subcutaneous | “0.4 IU/kg of Biocon Insulin N (100 IU/mL) administered once subcutaneously.” NCT04022304 ↗ |